Read today’s Kaiser Health News
About pharma
Novo Nordisk ends deal with Hims & Hers over sales of Wegovy copycats; HIMS drops 34%: Novo Nordisk said it is ending its collaboration with Hims & Hers due to concerns about the telehealth company's sales and promotion of cheaper knock-offs of the weight loss drug Wegovy.
Novo Nordisk in April said it would offer Wegovy through several telehealth companies, such as Hims & Hers, to expand access to the blockbuster injection now that it is no longer in short supply in the U.S.
But Novo Nordisk said Hims & Hers has "failed to adhere to the law which prohibits mass sales of compounded drugs" and accused the telehealth company of "deceptive" marketing that is putting patient safety at risk.
The 25 most expensive hospital drugs FYI
10 drug shortages causing the greatest strain in hospitals: Vizient FYI
About the public’s health
What the Texas food label law means for the rest of America: The first-of-its-kind legislation requires labels on foods containing 44 dyes or additives commonly found in the country’s food supply, such as in baked goods, candy and drinks. The new mandate will set off a scramble within the food industry, which must decide whether to reformulate its products to avoid warning labels, add the newly mandated language, stop selling certain products in Texas or file lawsuits against the measure.